Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
about
Standard cystectomy fits all: truth or myth?Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomenaSurgical resection of urological tumor metastases following medical treatmentRobotic versus open radical cystectomy: an updated systematic review and meta-analysisSentinel lymph node biopsy in bladder cancer: Systematic review and technology updateCurrent and potential applications of host-defense peptides and proteins in urologyEndoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial OutcomesBladder Sparing Approaches for Muscle-Invasive Bladder CancersBeyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?EZH2 in Bladder Cancer, a Promising Therapeutic TargetRadical cystectomy: do we need standardization?Quantitative ultrasound imaging of therapy response in bladder cancer in vivo.Standards of the Polish Ultrasound Society - update. Ultrasound examination of the kidneys, ureters and urinary bladder.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov.Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma.Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Diagnosis of bladder cancer and prediction of survival by urinary metabolomicsAccelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityInhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review.Robot-assisted radical cystectomy with intracorporeal neobladder diversion: The Karolinska experience.High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC)miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitroPrognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer.Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer.Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerTargeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic featuresAre urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study.Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancerClinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder.Readmission after robot-assisted radical cystectomy: outcomes and predictors at 90-day follow-up.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.
P2860
Q26774347-85512CC9-D57F-4B8A-A064-456163ABA6E1Q26860953-DCEC276A-8275-46E2-87CC-FD49F08E822EQ27013035-4DF8E7A7-718D-40C8-81FF-34E4C61F435DQ27014781-8FCE4280-1FDA-4FA3-9BCE-96D6B8845D5AQ27027693-376C569A-6501-4B77-9E92-2952443E79B6Q27027719-13FD6572-642A-4020-BC39-B4350D21A51EQ27320007-CF65DB3F-F376-4D31-9F4C-E27DF7EFA103Q28072814-DE968EA8-BE53-4540-B247-5F08BBA6149BQ28079221-5043C67A-4791-48C8-B6F6-26CD6E28FD3EQ28082054-41E8F863-B207-4132-9380-6E1C1481165EQ30240141-D3364438-C40A-4077-A85D-AAA452DE0743Q30383168-AB1F769E-BB05-4AE1-B35E-1B3EDECA4EFFQ30396120-ECC3A4EB-CEA0-4291-99D4-EB64E48ED956Q30485127-E6FFBDF0-E885-4085-B8A8-1BC72BE579BAQ30683510-E42DA7DC-5811-40DE-9C96-1911C3E17789Q30839472-08E1975F-4574-4634-9A07-92BB60743CC1Q30870825-873D6252-B881-42AD-8A8B-9BFEFCD7CDC8Q33662842-61D7F2B2-28B8-4861-A8C8-F39CA5241FDBQ33688951-A7443F22-7E82-4709-9A69-F4BE03A44D16Q33729078-F190660E-A737-42A5-9D7E-CCDF8F2B039EQ33755719-F8F66918-5947-438C-B26D-B3A5B6BB2F88Q33758673-7DA7FCE3-46DF-4893-8B60-B38547DB9F81Q33928633-E0C7057E-9BA6-4757-9A1D-56984CCC47DEQ33995446-2C564B60-BF42-415D-9CF9-CD9EA561CB09Q34184763-7B63002E-1574-4218-8027-7DED69043E59Q34337059-DCD897A7-7CF2-40C0-A02C-7BFD80479336Q34350342-70378A95-32B6-4C57-A3FE-B31BDE3AFD2EQ34492819-1A72911B-A6A8-4059-A5B6-14323656C254Q34506226-FCCA7EC8-7235-460D-84A5-123C2DF999BEQ34579038-10056D5A-3FD0-4E47-993E-6FF92570A6BFQ34581376-AC5EB54D-9A93-448A-914F-01EE8D9D7288Q34788410-D1DC899F-F847-4F15-8416-9D815C587CDCQ35040383-287A88A3-BD48-426C-A869-0F5629031B20Q35050111-18842B32-AF43-40C0-A47C-2064726A71FEQ35137483-06216EC1-065C-45B1-8AFD-885B3D591602Q35205137-06E21361-718C-4613-9A76-940B6DE46295Q35406622-D15019AF-ABAC-4C16-8C31-A811554609EEQ35533836-4402D8A4-B3C5-45A2-8A13-B71B3F287B06Q35606282-9B2405DB-A792-492B-BB7F-66A605FCAA8FQ35671292-D34E0EDB-E402-4394-A073-1DE2512D9424
P2860
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@en
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@nl
type
label
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@en
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@nl
prefLabel
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@en
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
@nl
P2093
P1433
P1476
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines
@en
P2093
Amir Sherif
Arnulf Stenzl
Axel S Merseburger
European Association of Urology (EAU)
J Alfred Witjes
Maria De Santis
Markus A Kuczyk
Nigel C Cowan
P304
P356
10.1016/J.EURURO.2011.03.023
P407
P577
2011-03-23T00:00:00Z